

Profession : Bio-Entrepreneur 2009, Entreprendre en Biotech
Santé, Paris, Mars 12 et 13, 2009

Ingénierie de la Santé et Biotech

L'OUVERTURE ET L'INDUSTRIALISATION DES BIOTECHNOLOGIES EN
MARCHÉ

LES 12 ATOUTS DE LA SUISSE

Oreste Ghisalba

Swiss Biotech Association and
Swiss Innovation Promotion Agency CTI

Swiss Biotech and Life sciences Sectors – 12 Strong Points

Switzerland has:

- Traditionally a very high scientific performance ranking among the OECD countries in: Life Sciences, Physical & Chemical Sciences and Engineering, Computer & Technology (CEST-ranking)
- A strong performance in innovation and translation of scientific results à European Champion in 2008 according to latest European Innovation Scoreboard
- A powerful and active Biotech Association (180 company members) and in addition a powerful pharmaceutical and chemical industry. Four highly active regional bioclusters (Basel, Zurich, Bioalps, Biopolo Ticino)
- A well balanced mix of core biotech companies and biotech suppliers/enablers
- Important R&D activities carried by private industry (in-house research and foundation-based research institutes)
- An optimal distribution of tasks between “tailor-made” federal agencies with important participation of experts from academia and industry; including excellent R&D funding, KTT support and start-up support by CTI; special programs of SNSF (NCCR und NRP)

Swiss Biotech and Life sciences Sectors – 12 Strong Points (2)

Switzerland has:

- Optimal conditions for innovation and technology transfer --> private and federal support
- Very significant activities in founding new companies (Start-ups and Spin-offs)
- A strong product pipeline (preclinical to phase III) for both public and private biotech companies
- Active private investors and VC companies/funds
- R&D in Switzerland is “multi- and transcultural” ($\geq 50\%$ of PhD-students and postdocs are of non-Swiss origin)
- Access to multi- and international research programmes and institutions